Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936413 | 0.93 | HMGCR (0.51) | HMGCRHSP90AB1HPGDTSHRALDH1A1 | |
| SCHEMBL28113527 | 0.86 | HMGCR (0.56) | HMGCRHSP90AB1HPGDTSHRALDH1A1 | |
| SCHEMBL4841923 | 0.84 | HMGCR (0.58) | HMGCRHSP90AB1HPGDTSHRALDH1A1 | |
| SCHEMBL15364117 | 0.81 | HMGCR (0.55) | HMGCRHSP90AB1HPGDTSHRALDH1A1 | |
| SCHEMBL8547285 | 0.80 | KDM4E (0.42) | HMGCRHSP90AB1TSHRALDH1A1HSD17B10 | |
| SCHEMBL22804304 | 0.80 | HMGCR (0.50) | HMGCRHSP90AB1HPGDTSHRALDH1A1 | |
| SCHEMBL29368970 | 0.80 | HMGCR (0.50) | HMGCRHSP90AB1HPGDTSHRALDH1A1 | |
| SCHEMBL7171606 | 0.79 | CA1 (0.53) | HPGDTSHRALDH1A1HSD17B10CA9 | |
| SCHEMBL3892816 | 0.79 | HTT (0.47) | HPGDALDH1A1CA9POLBMEN1 | |
| SCHEMBL19425899 | 0.79 | HSP90AB1 (0.50) | HMGCRHSP90AB1HPGDTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| WO-2008039418-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080051430-A1 | Acylated Piperidine Derivatives as Melanocortin 4-Receptor Agonists | MERCK & CO., INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051430-A1 | Acylated Piperidine Derivatives as Melanocortin 4-Receptor Agonists | MERCK & CO., INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051430-A1 | Acylated Piperidine Derivatives as Melanocortin 4-Receptor Agonists | MERCK & CO., INC. | 2008-02-28 | — | — | US | disclosed |
| EP-1773347-A4 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1773347-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006019787-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | HMGCR 2398/4885HSP90AB1 2385/4885HPGD 1646/4885 |
| US-20080051430-A1 | Acylated Piperidine Derivatives as Melanocortin 4-Receptor Agonists | MC4R, MC5R, MC3R | HMGCR 3752/4885HSP90AB1 3161/4885HPGD 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.